Treatment for Brain Metastases

Publication Date: December 21, 2021
Last Updated: March 27, 2023

Treatment

Recommendation 1.1

Surgery may be offered for patients with brain metastases, considering the following factors: Patients with suspected brain metastases without a primary cancer diagnosis may benefit from surgery to attain a diagnosis and undergo tumor removal.

  • Patients with large tumors with mass effect likely benefit from surgery.
  • Patients with multiple brain metastases and/or uncontrolled systemic disease are less likely to benefit from surgery unless the remaining disease is controllable via other measures.
( EB , , , M )
(Evidence quality: mixed)
3336

Recommendation 1.2

Where surgery is considered, no recommendation regarding the method of resection (piecemeal vs. en bloc) can be made.

( IC , L , , )
3336

Recommendation 1.3

No recommendation can be made for or against LITT.

( IC , L , , )
3336

Recommendation 2.1

Patients with symptomatic brain metastases should be offered local therapy (radiosurgery/radiation therapy and/or surgery) as recommended in this guideline regardless of the systemic therapy used for the systemic disease.

( EB , H , , S )
3336

Recommendation 2.2

For patients with asymptomatic brain metastases, local therapy should not be deferred unless deferral is specifically recommended in Recommendations 2.3 through 2.7 of this guideline. The decision to defer local therapy should be based on a multi-disciplinary discussion (neuro or medical oncology, neurosurgery, and radiation oncology) of the potential benefits and harms the patient may experience.

( EB , H , , S )
3336

Recommendation 2.3 

Osimertinib or icotinib may be offered to patients with asymptomatic brain metastases from EGFR-mutant NSCLC. If these agents are used, local therapy may be delayed until there is evidence of intracranial progression.

( IC , L , , W )

Qualifying Statement: The expert panel recognizes that as of this publication, icotinib is not approved by the US Food & Drug Administration (FDA) or the European Medicines Agency.

3336

Recommendation 2.4

Alectinib, brigatinib, or ceritinib may be offered to patients with asymptomatic brain metastases from ALK-rearranged NSCLC. If these agents are used, local therapy may be delayed until there is evidence of intracranial progression.

( IC , L , , W )
3336

Recommendation 2.5

Pembrolizumab may be offered to patients with asymptomatic brain metastases from immunotherapy-naive PD-L1 expressing NSCLC who are also receiving pemetrexed and a platinum agent.

( IC , L , , W )

Note: See Recommendation 2.2 regarding local therapy.

3336

Recommendation 2.6

Ipilimumab plus nivolumab (for all patients regardless of BRAF status) or dabrafenib plus trametinib (for patients with BRAF-V600E mutation) may be offered to patients with asymptomatic brain metastases from melanoma. If these agents are used, local therapy may be delayed until there is evidence of intracranial progression.

( IC , L , , W )
3336

Recommendation 2.7

The combination of tucatinib, trastuzumab, and capecitabine may be offered to patients with HER2 positive metastatic breast cancer who have asymptomatic brain metastases and have progressed on previous trastuzumab, pertuzumab, and/or trastuzumab emtansine-based therapy. If these agents are used, local therapy may be delayed until there is evidence of intracranial progression.

( EB , L , , W )
3336

Recommendation 3.1

Radiation therapy should not be offered to patients with asymptomatic brain metastases who have:

  1. Performance status KPS ≤50 or less, OR
  2. Performance status KPS <70 and no systemic therapy options.
( EB , L , , M )
3336

Recommendation 3.2

SRS alone (as opposed to WBRT or combination of WBRT and SRS) should be offered to patients with 1 to 4 unresected brain metastases, excluding small cell carcinoma.

( EB , I , , M )

Qualifying Statement: The inclusion criteria of the randomized trials that underlie this recommendation were generally tumors of less than 3 or 4 cm diameter and did not include radioprotectant strategies of memantine or hippocampal avoidance.

3336

Recommendation 3.3

SRS alone should be offered to patients with 1 to 2 resected brain metastases if the surgical cavity can be safely treated and considering the extent of remaining intracranial disease.

( EB , I , , M )

Qualifying Statement: The randomized trials upon which this recommendation is based were of single-fraction SRS and conventional WBRT (without radioprotectant strategies of memantine or hippocampal avoidance).

3336


Recommendation 3.4

SRS, WBRT, and the combination of SRS plus WBRT are all reasonable options for patients with more than 4 unresected or more than 2 resected brain metastases and better performance status (e.g., KPS ≥70). SRS may be preferred for patients with better prognosis or where systemic therapy that is known to be active in the central nervous system is available.

( IC , L , , W )
3336


Recommendation 3.5

Memantine and hippocampal avoidance should be offered to patients who will receive WBRT and have no hippocampal lesions and 4 months or more expected survival.

( EB , H , , S )
3336

Recommendation 3.6

Radiation sensitizing agents should not be offered to patients.

( EB , L , , S )
3336


Recommendation 4.1

For patients who will receive both radiation therapy and surgery, no recommendation regarding the specific sequence of therapy can be made.

( IC , L , , )
3336

ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate.

Additional information, which may include data supplements, slide sets, and other clinical tools and resources, is available at www.asco.org/neurooncology-guidelines.

Recommendation Grading

Disclaimer

The information in this patient summary should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.

Overview

Title

Treatment for Brain Metastases

Authoring Organizations

Publication Month/Year

December 21, 2021

Last Updated Month/Year

February 12, 2024

Document Type

Guideline

Country of Publication

US

Inclusion Criteria

Male, Female, Adolescent, Adult, Child, Older adult

Health Care Settings

Ambulatory, Hospital, Outpatient, Radiology services, Operating and recovery room

Intended Users

Nurse, nurse practitioner, physician, physician assistant

Scope

Treatment, Management

Diseases/Conditions (MeSH)

D001932 - Brain Neoplasms

Keywords

brain cancer

Supplemental Methodology Resources

Data Supplement

Methodology

Number of Source Documents
197
Literature Search Start Date
January 1, 2015
Literature Search End Date
August 17, 2020